
1. malar j. 2012 may 2;11:146.

early treatment failure treatment plasmodium falciparum malaria with
atovaquone-proguanil republic ivory coast.

wurtz n(1), pascual a, marin-jauffre a, bouchiba h, benoit n, desbordes m,
martelloni m, pommier de santi v, richa g, taudon n, pradines b, briolant s.

author information: 
(1)unité de parasitologie - unité de recherche pour les maladies infectieuses et 
tropicales emergentes - umr 6236, institut de recherche biomédicale des armées,
marseille, france. nathalie_wurtz@yahoo.fr

the increased spread drug-resistant malaria highlights need for
alternative drugs treatment chemoprophylaxis. combination of
atovaquone-proguanil (malarone®) shown high efficacy plasmodium
falciparum mild side-effects. treatment failures attributed
to suboptimal dosages parasite resistance resulting point mutation
in cytochrome b gene. paper, case early treatment failure was
reported patient treated atovaquone-proguanil; failure not
associated mutation parasite cytochrome b gene, impaired drug 
bioavailability, re-infection.

doi: 10.1186/1475-2875-11-146 
pmcid: pmc3447648
pmid: 22551095  [indexed medline]

